RESULTS: Before treatment, the levels of GH and
IGF-1 were not significantly different among groups.
After treatment, the levels of GH (0.71 +/- 0.34 vs 0.96 +/- 0.48) and
IGF-1 (95.64 +/- 21.11 vs 111.64 +/- 23.14)in CHF experimental group were higher than those before the treatment. In CHF control group, the levels of GH(0.81 +/- 0.32 vs 0.79 +/- 0.29) and
IGF-1 (97.82 +/- 19.74 vs 99.65 +/- 20.11) had no significant change after the treatment.
After treatment, the levels of GH (0.96 +/- 0.48 vs 0.79 +/- 0.29) and
IGF-1 (111.64 +/- 23.14 vs 99.65 +/- 20.11) in CHF experimental group were higher compared with that of CHF control group. Before treatment, the serum levels of
LDL-C, HDL-C, TC and TG had no significant difference among groups.
After treatment,the levels of
LDL-C (2.11 +/- 0.82 vs 1.76 +/- 0.51) and TC (3.78 +/- 1.34 vs 3.21 +/- 1.17) in CHF experimental group were lower than those before the treatment. However, the levels of HDL-C (1.10 +/- 0.31 vs 0.99 +/- 0.28)and TG (1. 89 +/- 1.07 vs 1.66 +/- 0.95) had no significant change after the treatment compared with before treatment. In CHF control group, the serum
lipid levels had no significant change after the treatment.
CONCLUSION: As the treatment of rhGH for aged male patients with chronic
heart failure, GH influences lipid metabolism, which reduces the level of
LDL-C, TC. However GH has no effects on the serum HDL-C and TG level. With the treatment of rhGH for long-term, lipid metabolism should be paid attention,and the treatment for blood
lipid reduction should be adjusted in time.